scholarly journals Informed Assent

2020 ◽  
Author(s):  
Keyword(s):  
Informed Assent

Informed Nondissent Rather Than Informed Assent

CHEST Journal ◽  
2008 ◽  
Vol 133 (1) ◽  
pp. 320-321 ◽  
Author(s):  
Alexander A. Kon
Keyword(s):  
Informed Assent

Adolescent Perspectives on Informed Assent for an HIV Vaccine Trial

2010 ◽  
Vol 46 (2) ◽  
pp. S28 ◽  
Author(s):  
Diane Blake ◽  
Celeste Lemay ◽  
Margaret Kearney ◽  
Kathleen Mazor
Keyword(s):  
Vaccine Trial ◽  
Hiv Vaccine ◽  
Informed Assent

Informed Assent and Medical Education: Response

CHEST Journal ◽  
2008 ◽  
Vol 133 (4) ◽  
pp. 1051-1052
Author(s):  
Robert A. Burt ◽  
J. Randall Curtis
Keyword(s):  
Medical Education ◽  
Informed Assent

Informed Assent and Medical Education: Response

CHEST Journal ◽  
2008 ◽  
Vol 133 (4) ◽  
pp. 1052
Author(s):  
Constantine A. Manthous
Keyword(s):  
Medical Education ◽  
Informed Assent

Informed Nondissent Rather Than Informed Assent: Response

CHEST Journal ◽  
2008 ◽  
Vol 133 (1) ◽  
pp. 321
Author(s):  
J. Randall Curtis ◽  
Robert A. Burt
Keyword(s):  
Informed Assent

Informed Assent and Medical Education

CHEST Journal ◽  
2008 ◽  
Vol 133 (4) ◽  
pp. 1051
Author(s):  
Christopher Dale
Keyword(s):  
Medical Education ◽  
Informed Assent

Cost-Conscious Growth-Promoting Treatment: When Discretion Is the Better Part of Value

2018 ◽  
Vol 90 (3) ◽  
pp. 145-150 ◽  
Author(s):  
David B. Allen
Keyword(s):  
Health Care ◽  
Short Stature ◽  
Growth Promotion ◽  
Human Growth ◽  
New Era ◽  
Short Children ◽  
Growth Promoting ◽  
Informed Assent ◽  
Care Costs ◽  
Adult Stature

Assessing cost-effectiveness of human growth hormone (hGH) treatment to augment height is complicated by uncertainty about how best to measure its therapeutic effect. Cost-conscious growth promotion practice, however, is possible and likely an emerging practical requisite as health care payers increasingly deny the medical necessity of and restrict support for short stature treatment. The increase in denials is not surprising given the expansion and continued high cost of hGH treatment, debate about the value of such treatment, and universal need to restrain burgeoning health care costs. Renunciation of sweeping payer rejection of hGH-for-height treatment is strengthened by cost-conscious practices that (1) recommend no treatment for most short children and restrict treatment to severe, likely disabling short stature; (2) initiate hGH treatment only after evidence-based informed assent; (3) utilize alternative less costly and less invasive options when possible; (4) minimize hGH treatment duration and dosage; and (5) resist enhancement of normal adult stature. A new era of cost-conscious hGH prescribing that prompts thoughtful restraint in hGH use could help preserve hGH approval for children most in need of treatment.

Sign in / Sign up

Export Citation Format

Share Document